Roche’s Master Plan: Perjeta Gains Early Breast Cancer Approval, Late-Stage Kadcyla Data

Perjeta’s approval in neoadjuvant breast cancer signals paradigm change as first approval under new pathway. Meanwhile, antibody-drug conjugate Kadcyla proves its worth in heavily pretreated, advanced breast cancer.